Quidel Co. (NASDAQ:QDEL) CEO Douglas C. Bryant sold 25,250 shares of the stock in a transaction dated Friday, March 29th. The shares were sold at an average price of $65.64, for a total transaction of $1,657,410.00. Following the completion of the transaction, the chief executive officer now directly owns 302,237 shares of the company’s stock, valued at approximately $19,838,836.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
NASDAQ QDEL traded up $0.40 during trading on Monday, hitting $64.34. The stock had a trading volume of 99,248 shares, compared to its average volume of 233,211. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.21 and a quick ratio of 0.79. The company has a market cap of $2.52 billion, a P/E ratio of 22.82, a PEG ratio of 0.92 and a beta of 1.37. Quidel Co. has a one year low of $44.27 and a one year high of $77.63.
Quidel (NASDAQ:QDEL) last announced its quarterly earnings data on Wednesday, February 13th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.21. The business had revenue of $132.59 million during the quarter, compared to the consensus estimate of $132.26 million. Quidel had a net margin of 14.20% and a return on equity of 31.73%. The firm’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 earnings per share. As a group, equities research analysts expect that Quidel Co. will post 2.77 EPS for the current year.
A number of research analysts recently commented on QDEL shares. BidaskClub downgraded shares of Quidel from a “strong-buy” rating to a “buy” rating in a report on Friday, April 5th. Zacks Investment Research downgraded shares of Quidel from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. Barclays reaffirmed a “buy” rating and issued a $74.00 price target on shares of Quidel in a report on Friday, February 15th. Finally, ValuEngine raised shares of Quidel from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $72.67.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/16/insider-selling-quidel-co-qdel-ceo-sells-1657410-00-in-stock.html.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Story: Producer Price Index (PPI)
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.